Harmony Biosciences Holdings Inc. (HRMY): Price and Financial Metrics
GET POWR RATINGS... FREE!
HRMY Stock Price Chart Interactive Chart >
HRMY Price/Volume Stats
| Current price | $31.99 | 52-week high | $52.74 |
| Prev. close | $32.64 | 52-week low | $25.46 |
| Day low | $31.86 | Volume | 171,100 |
| Day high | $32.84 | Avg. volume | 159,304 |
| 50-day MA | $29.83 | Dividend yield | N/A |
| 200-day MA | $35.65 | Market Cap | 1.82B |
Harmony Biosciences Holdings Inc. (HRMY) Company Bio
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product WAKIX is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
Latest HRMY News From Around the Web
Below are the latest news stories about Harmony Biosciences Holdings Inc that investors may wish to consider to help them evaluate HRMY as an investment opportunity.
/C O R R E C T I O N -- Harmony Biosciences/Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced results of a new analysis evaluating number needed to treat (NNT) and effect sizes for treatment with WAKIX® (pitolisant) that demonstrates the magnitude of its clinical effectiveness for excessive daytime sleepiness (EDS) and cataplexy in adults w |
Harmony Biosciences Announces Applications for 2021 Patients At The Heart Grant Program Open June 9PLYMOUTH MEETING, Pa. , June 9, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ: HRMY ), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced applications for its Patients at the Heart Grant Program open Wednesday, June 9, 2021 for patient-centric organizations working to support and address the challenges of people living with sleep disorders and rare diseases who experience excessive daytime sleepiness (EDS). … Full story available on Benzinga.com |
Harmony Biosciences To Present New Data Analyses For WAKIX® (pitolisant) At The SLEEP 2021 Annual MeetingHarmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that results from two post-hoc analyses from the clinical development program for WAKIX® (pitolisant) will be presented at the 35th Annual Meeting of the Associated Professional Sleep Societies (APSS), known as "SLEEP 2021." The meeting will be hel |
Harmony Biosciences to Participate in Three Investor Conferences in JuneHarmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that Harmony's President and CEO, John Jacobs, will participate in fireside chats and host investor meetings at the following upcoming virtual conferences: |
Harmony Biosciences: Looking Very Compelling HerePhoto by oatawa/iStock via Getty Images Harmony Biosciences (HRMY) is a name that went public late in 2020 and attracted my interest from the get go. Harmony went public back in August and, like so many of the names going public around that time, has now seen a round-trip boom... |
HRMY Price Returns
| 1-mo | 14.74% |
| 3-mo | 6.07% |
| 6-mo | -19.90% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -11.51% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...